Global Neurological Disorder Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

  • receipt Report ID : 150564
  • calendar_today Published On: Apr, 2019
  • file_copy Pages: 116
  • list Pharmaceuticals and Healthcare

Several government initiatives across various countries to educate masses about the rise of various diseases and increasing healthcare sector producing new drugs are the prime reasons for growth of neurological disorder drugs market. European Parkinson’s Disease Association, in Europe is actively supporting research and development by campaigning to raise awareness, and providing medication to patients is boosting the overall neurological disorder drugs market. This region is also witnessing rising focus on research and development programs that will help in producing affordable and effective drugs. The countries are collectively spending on developing neurological disorder drugs thus, improving the revenue of the market during the forecast period.

Scope of the Report:

This report focuses on the Neurological Disorder Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Staggering increase in brain altering disorders such as Alzheimer’s, epilepsy, Parkinson’s, cerebrovascular, and sclerosis are promoting the pharmaceutical firms to tap into the significantly growing neurological disorder drugs market. This will potentially supplement the market growth in the coming years. Rise of several innovative drugs to manage these diseases will swell up the investments in the market. Increasing number of clinical trials are another reason boosting the market. Rise in geriatric population along with patients with strokes, migraines, and headaches leading to cerebrovascular diseases are likely to augment the growth of the market.

The worldwide market for Neurological Disorder Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.

Market Segment by Manufacturers, this report covers

Novartis AG

GlaxoSmithKline plc

Merck & Co.

Bayer AG

AstraZeneca

Boehringer Ingelheim GmbH

Teva Pharmaceutical

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Antipsychotic

Hypnotic & Sedative

Analgesics

Anticoagulants

Others

Market Segment by Applications, can be divided into

Hospital

Clinic

There are 15 Chapters to deeply display the global Neurological Disorder Drugs market.

Chapter 1, to describe Neurological Disorder Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Neurological Disorder Drugs, with sales, revenue, and price of Neurological Disorder Drugs, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Neurological Disorder Drugs, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, Neurological Disorder Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe Neurological Disorder Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Market Overview

1.1 Neurological Disorder Drugs Introduction

1.2 Market Analysis by Type

1.2.1 Antipsychotic

1.2.2 Hypnotic & Sedative

1.2.3 Analgesics

1.2.4 Anticoagulants

1.2.5 Others

1.3 Market Analysis by Applications

1.3.1 Hospital

1.3.2 Clinic

1.4 Market Analysis by Regions

1.4.1 North America (United States, Canada and Mexico)

1.4.1.1 United States Market States and Outlook (2013-2023)

1.4.1.2 Canada Market States and Outlook (2013-2023)

1.4.1.3 Mexico Market States and Outlook (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy)

1.4.2.1 Germany Market States and Outlook (2013-2023)

1.4.2.2 France Market States and Outlook (2013-2023)

1.4.2.3 UK Market States and Outlook (2013-2023)

1.4.2.4 Russia Market States and Outlook (2013-2023)

1.4.2.5 Italy Market States and Outlook (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

1.4.3.1 China Market States and Outlook (2013-2023)

1.4.3.2 Japan Market States and Outlook (2013-2023)

1.4.3.3 Korea Market States and Outlook (2013-2023)

1.4.3.4 India Market States and Outlook (2013-2023)

1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)

1.4.4 South America, Middle East and Africa

1.4.4.1 Brazil Market States and Outlook (2013-2023)

1.4.4.2 Egypt Market States and Outlook (2013-2023)

1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)

1.4.4.4 South Africa Market States and Outlook (2013-2023)

1.4.4.5 Nigeria Market States and Outlook (2013-2023)

1.5 Market Dynamics

1.5.1 Market Opportunities

1.5.2 Market Risk

1.5.3 Market Driving Force

2 Manufacturers Profiles

2.1 Novartis AG

2.1.1 Business Overview

2.1.2 Neurological Disorder Drugs Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Novartis AG Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.2 GlaxoSmithKline plc

2.2.1 Business Overview

2.2.2 Neurological Disorder Drugs Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 GlaxoSmithKline plc Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.3 Merck & Co.

2.3.1 Business Overview

2.3.2 Neurological Disorder Drugs Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Merck & Co. Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.4 Bayer AG

2.4.1 Business Overview

2.4.2 Neurological Disorder Drugs Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Bayer AG Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.5 AstraZeneca

2.5.1 Business Overview

2.5.2 Neurological Disorder Drugs Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 AstraZeneca Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.6 Boehringer Ingelheim GmbH

2.6.1 Business Overview

2.6.2 Neurological Disorder Drugs Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 Boehringer Ingelheim GmbH Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.7 Teva Pharmaceutical

2.7.1 Business Overview

2.7.2 Neurological Disorder Drugs Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 Teva Pharmaceutical Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

3 Global Neurological Disorder Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)

3.1 Global Neurological Disorder Drugs Sales and Market Share by Manufacturer (2016-2017)

3.2 Global Neurological Disorder Drugs Revenue and Market Share by Manufacturer (2016-2017)

3.3 Market Concentration Rate

3.3.1 Top 3 Neurological Disorder Drugs Manufacturer Market Share in 2017

3.3.2 Top 6 Neurological Disorder Drugs Manufacturer Market Share in 2017

3.4 Market Competition Trend

4 Global Neurological Disorder Drugs Market Analysis by Regions

4.1 Global Neurological Disorder Drugs Sales, Revenue and Market Share by Regions

4.1.1 Global Neurological Disorder Drugs Sales and Market Share by Regions (2013-2018)

4.1.2 Global Neurological Disorder Drugs Revenue and Market Share by Regions (2013-2018)

4.2 North America Neurological Disorder Drugs Sales and Growth Rate (2013-2018)

4.3 Europe Neurological Disorder Drugs Sales and Growth Rate (2013-2018)

4.4 Asia-Pacific Neurological Disorder Drugs Sales and Growth Rate (2013-2018)

4.5 South America Neurological Disorder Drugs Sales and Growth Rate (2013-2018)

4.6 Middle East and Africa Neurological Disorder Drugs Sales and Growth Rate (2013-2018)

5 North America Neurological Disorder Drugs by Countries

5.1 North America Neurological Disorder Drugs Sales, Revenue and Market Share by Countries

5.1.1 North America Neurological Disorder Drugs Sales and Market Share by Countries (2013-2018)

5.1.2 North America Neurological Disorder Drugs Revenue and Market Share by Countries (2013-2018)

5.2 United States Neurological Disorder Drugs Sales and Growth Rate (2013-2018)

5.3 Canada Neurological Disorder Drugs Sales and Growth Rate (2013-2018)

5.4 Mexico Neurological Disorder Drugs Sales and Growth Rate (2013-2018)

6 Europe Neurological Disorder Drugs by Countries

6.1 Europe Neurological Disorder Drugs Sales, Revenue and Market Share by Countries

6.1.1 Europe Neurological Disorder Drugs Sales and Market Share by Countries (2013-2018)

6.1.2 Europe Neurological Disorder Drugs Revenue and Market Share by Countries (2013-2018)

6.2 Germany Neurological Disorder Drugs Sales and Growth Rate (2013-2018)

6.3 UK Neurological Disorder Drugs Sales and Growth Rate (2013-2018)

6.4 France Neurological Disorder Drugs Sales and Growth Rate (2013-2018)

6.5 Russia Neurological Disorder Drugs Sales and Growth Rate (2013-2018)

6.6 Italy Neurological Disorder Drugs Sales and Growth Rate (2013-2018)

7 Asia-Pacific Neurological Disorder Drugs by Countries

7.1 Asia-Pacific Neurological Disorder Drugs Sales, Revenue and Market Share by Countries

7.1.1 Asia-Pacific Neurological Disorder Drugs Sales and Market Share by Countries (2013-2018)

7.1.2 Asia-Pacific Neurological Disorder Drugs Revenue and Market Share by Countries (2013-2018)

7.2 China Neurological Disorder Drugs Sales and Growth Rate (2013-2018)

7.3 Japan Neurological Disorder Drugs Sales and Growth Rate (2013-2018)

7.4 Korea Neurological Disorder Drugs Sales and Growth Rate (2013-2018)

7.5 India Neurological Disorder Drugs Sales and Growth Rate (2013-2018)

7.6 Southeast Asia Neurological Disorder Drugs Sales and Growth Rate (2013-2018)

8 South America Neurological Disorder Drugs by Countries

8.1 South America Neurological Disorder Drugs Sales, Revenue and Market Share by Countries

8.1.1 South America Neurological Disorder Drugs Sales and Market Share by Countries (2013-2018)

8.1.2 South America Neurological Disorder Drugs Revenue and Market Share by Countries (2013-2018)

8.2 Brazil Neurological Disorder Drugs Sales and Growth Rate (2013-2018)

8.3 Argentina Neurological Disorder Drugs Sales and Growth Rate (2013-2018)

8.4 Colombia Neurological Disorder Drugs Sales and Growth Rate (2013-2018)

9 Middle East and Africa Neurological Disorder Drugs by Countries

9.1 Middle East and Africa Neurological Disorder Drugs Sales, Revenue and Market Share by Countries

9.1.1 Middle East and Africa Neurological Disorder Drugs Sales and Market Share by Countries (2013-2018)

9.1.2 Middle East and Africa Neurological Disorder Drugs Revenue and Market Share by Countries (2013-2018)

9.2 Saudi Arabia Neurological Disorder Drugs Sales and Growth Rate (2013-2018)

9.3 UAE Neurological Disorder Drugs Sales and Growth Rate (2013-2018)

9.4 Egypt Neurological Disorder Drugs Sales and Growth Rate (2013-2018)

9.5 Nigeria Neurological Disorder Drugs Sales and Growth Rate (2013-2018)

9.6 South Africa Neurological Disorder Drugs Sales and Growth Rate (2013-2018)

10 Global Neurological Disorder Drugs Market Segment by Type

10.1 Global Neurological Disorder Drugs Sales, Revenue and Market Share by Type (2013-2018)

10.1.1 Global Neurological Disorder Drugs Sales and Market Share by Type (2013-2018)

10.1.2 Global Neurological Disorder Drugs Revenue and Market Share by Type (2013-2018)

10.2 Antipsychotic Sales Growth and Price

10.2.1 Global Antipsychotic Sales Growth (2013-2018)

10.2.2 Global Antipsychotic Price (2013-2018)

10.3 Hypnotic & Sedative Sales Growth and Price

10.3.1 Global Hypnotic & Sedative Sales Growth (2013-2018)

10.3.2 Global Hypnotic & Sedative Price (2013-2018)

10.4 Analgesics Sales Growth and Price

10.4.1 Global Analgesics Sales Growth (2013-2018)

10.4.2 Global Analgesics Price (2013-2018)

10.5 Anticoagulants Sales Growth and Price

10.5.1 Global Anticoagulants Sales Growth (2013-2018)

10.5.2 Global Anticoagulants Price (2013-2018)

10.6 Others Sales Growth and Price

10.6.1 Global Others Sales Growth (2013-2018)

10.6.2 Global Others Price (2013-2018)

11 Global Neurological Disorder Drugs Market Segment by Application

11.1 Global Neurological Disorder Drugs Sales Market Share by Application (2013-2018)

11.2 Hospital Sales Growth (2013-2018)

11.3 Clinic Sales Growth (2013-2018)

12 Neurological Disorder Drugs Market Forecast (2018-2023)

12.1 Global Neurological Disorder Drugs Sales, Revenue and Growth Rate (2018-2023)

12.2 Neurological Disorder Drugs Market Forecast by Regions (2018-2023)

12.2.1 North America Neurological Disorder Drugs Market Forecast (2018-2023)

12.2.2 Europe Neurological Disorder Drugs Market Forecast (2018-2023)

12.2.3 Asia-Pacific Neurological Disorder Drugs Market Forecast (2018-2023)

12.2.4 South America Neurological Disorder Drugs Market Forecast (2018-2023)

12.2.5 Middle East and Africa Neurological Disorder Drugs Market Forecast (2018-2023)

12.3 Neurological Disorder Drugs Market Forecast by Type (2018-2023)

12.3.1 Global Neurological Disorder Drugs Sales Forecast by Type (2018-2023)

12.3.2 Global Neurological Disorder Drugs Market Share Forecast by Type (2018-2023)

12.4 Neurological Disorder Drugs Market Forecast by Application (2018-2023)

12.4.1 Global Neurological Disorder Drugs Sales Forecast by Application (2018-2023)

12.4.2 Global Neurological Disorder Drugs Market Share Forecast by Application (2018-2023)

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.1.3 Marketing Channel Future Trend

13.2 Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Data Source

List of Tables and Figures

Figure Neurological Disorder Drugs Picture

Table Product Specifications of Neurological Disorder Drugs

Figure Global Sales Market Share of Neurological Disorder Drugs by Ty

Please fill the form below, to recieve the report sample


+1